momelotinib,Danazol
sierra oncology,gsk,lannett
['momelotinib', '#myelof', 'gsk']
#momelotinib in patients with #myelofibrosis
gsk announced that, at 48 weeks, momelotinib maintained total symptom response and transfusion independence in patients who responded in the first 24 weeks. #ash22 #ash2022 #bloodmatters #hematology
#iPharmaCenter is a #website which covers #pharmaceutical and #healthcare #news plus #blogs #diseases #drugs #healthcaresystems #globalhealth #pharma